Inactive Instrument
Peregrine Pharmaceuticals Share Price Nasdaq
Stocks
US7136613046
Pharmaceuticals
| Market Cap | 80Cr 68Cr 64Cr 59Cr 110Cr 7.64TCr 111.45Cr 756.52Cr 295.02Cr 3.84TCr 299.98Cr 293.45Cr 13TCr | P/E 2023 |
2,007x | P/E 2024 | -3.42x |
|---|---|---|---|---|---|
| Enterprise Value | 96Cr 83Cr 77Cr 71Cr 132.77Cr 9.23TCr 134.52Cr 913.08Cr 356.07Cr 4.63TCr 362.06Cr 354.18Cr 15TCr | EV / Sales 2023 |
8.58x | EV / Sales 2024 | 4.64x |
| Free-Float |
98.58% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -2.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 15/09/2025 | |
Richard McAvoy
DFI | Director of Finance/CFO | - | 01/06/2026 |
David Stewart
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.83% | +7.69% | - | - | 80Cr | |
| +0.90% | +3.80% | +41.49% | -0.81% | 8.33TCr | |
| +8.86% | +129.20% | +435.14% | +25.70% | 5.79TCr | |
| +0.48% | +25.64% | -21.85% | -35.91% | 5.78TCr | |
| -1.46% | +0.19% | -2.06% | +32.21% | 5.17TCr | |
| -0.05% | +2.83% | +10.20% | +171.85% | 4.93TCr | |
| +1.13% | +3.31% | +55.61% | -18.13% | 3.2TCr | |
| +0.46% | +6.37% | +50.29% | +97.70% | 2.59TCr | |
| -2.98% | +4.30% | -0.50% | +187.01% | 2.27TCr | |
| -1.26% | -0.83% | +56.44% | +108.83% | 1.69TCr | |
| Average | +0.33% | +20.47% | +69.42% | +63.16% | 4.42TCr | |
| Weighted average by Cap. | +1.24% | +24.98% | +80.04% | +44.09% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 15Cr 13Cr 12Cr 11Cr 21Cr 1.43TCr 21Cr 141.35Cr 55Cr 717.43Cr 56Cr 55Cr 2.37TCr | 14Cr 12Cr 11Cr 10Cr 19Cr 1.34TCr 20Cr 132.49Cr 52Cr 672.47Cr 53Cr 51Cr 2.22TCr |
| Net income | 6L 5L 4L 4L 8L 5.36Cr 8L 53.03L 20.68L 2.69Cr 21.03L 20.57L 8.9Cr | -14Cr -12Cr -11Cr -10Cr -19Cr -1.35TCr -20Cr -133.29Cr -52Cr -676.52Cr -53Cr -52Cr -2.24TCr |
| Net Debt | 15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 21Cr 143.2Cr 56Cr 726.83Cr 57Cr 56Cr 2.4TCr | 17Cr 14Cr 13Cr 12Cr 23Cr 1.58TCr 23Cr 156.56Cr 61Cr 794.63Cr 62Cr 61Cr 2.63TCr |
Employees
-
Sector
Pharmaceuticals
